Black Diamond Therapeutics, Inc.

Equities

BDTX

US09203E1055

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.89 ^USD	+15.26%		+11.98%	+109.61%

Apr. 11	Black Diamond Therapeutics, Inc. Announces Board and Committee Changes	CI
Apr. 08	Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating	MT

Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 12, 2024 at 07:21 am EDT

Black Diamond Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 82.44 million compared to USD 91.17 million a year ago. Basic loss per share from continuing operations was USD 1.88 compared to USD 2.52 a year ago.

Latest news about Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. Announces Board and Committee Changes	Apr. 11	CI
Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating	Apr. 08	MT
Black Diamond Therapeutics Says BDTX-1535 Potentially Inhibits Non-Classical Mutations in Non-Small Cell Lung Cancer Patients	Apr. 08	MT
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
Black Diamond Therapeutics, Inc. Announces Resignation of Rajeev Shah from Board of Directors, Including as A Member of the Audit Committee of the Board	Jan. 18	CI
Black Diamond Therapeutics, Inc. Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM	Dec. 13	CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Black Diamond Therapeutics, Inc. Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535	23-10-14	CI
Black Diamond Therapeutics, Inc. Announces Management Changes	23-09-18	CI
Black Diamond Therapeutics, Inc. Announces Chief Executive Officer Changes	23-09-18	CI
Black Diamond Therapeutics, Inc. Doses First Patients in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer	23-09-11	CI
Certain Restricted Stock Units of Black Diamond Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-AUG-2023.	23-08-28	CI
Certain Warrants of Black Diamond Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-AUG-2023.	23-08-28	CI
Certain Stock Options of Black Diamond Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-AUG-2023.	23-08-28	CI
Certain Common Stock of Black Diamond Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-AUG-2023.	23-08-28	CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Piper Sandler Initiates Black Diamond Therapeutics With Overweight Rating, $11 Price Target	23-07-14	MT
Sector Update: Health Care Stocks Steady Premarket Monday	23-07-10	MT
Black Diamond Therapeutics Discloses Institutional Shareholder Equity Stake Expansion; Shares Jump Premarket	23-07-10	MT
Stifel Upgrades Black Diamond Therapeutics to Buy From Hold, Adjusts Price Target to $10 From $2	23-06-30	MT
Black Diamond Therapeutics Prices $75 Million Common Stock Offering	23-06-30	MT
Top Premarket Decliners	23-06-29	MT
Black Diamond Therapeutics Launches $75 Million Stock Offering; Shares Drop After-Hours	23-06-28	MT
Insider Sell: Black Diamond Therapeutics	23-06-28	MT

Chart Black Diamond Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Companyâs MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The Company is also focused on a development candidate against an undisclosed, validated oncogene.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.89 USD

Average target price

12.8 USD

Spread / Average Target

+117.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BLACK DIAMOND THERAPEUTICS, INC.	+109.61%	309M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs